Engineering and Technology
| Open Access |
DOI: Bridging Low-Code/No-Code and MES in Pharmaceutical and Medical Device Manufacturing
Dhaval Sikligar , Digital Manufacturing / Industrial Information Systems / Pharmaceutical EngineeringAbstract
Pharmaceutical and medical device manufacturers operate in a highly regulated environment where operational efficiency, data integrity, and regulatory compliance must coexist. Manufacturing Execution Systems (MES) have traditionally served as the backbone of digital manufacturing, enforcing standardized workflows, batch traceability, electronic records, and compliance with regulations such as FDA 21 CFR Part 11, EU Annex 11, and Good Manufacturing Practice (GMP). While MES solutions provide robust governance and audit readiness, they are often associated with long implementation cycles, high costs, and limited flexibility in addressing shop-floor requirements that change quickly.
Low-Code/No-Code (LCNC) platforms have emerged as a complementary enabler of agile application development. Platforms such as Tulip and Mendix allow engineers, quality teams, and business users to design and deploy applications rapidly using visual modeling tools. These platforms support digital work instructions, operator performance monitoring, downtime tracking, and AI-driven defect detection, but face challenges related to scalability, validation, and compliance when deployed independently in regulated settings.
This paper proposes a hybrid framework that strategically integrates LCNC platforms with MES, positioning MES as the system of record for validated, GxP-critical processes and LCNC as a flexible innovation layer for rapid digitization. The framework draws on a qualitative, conceptual research methodology grounded in industry practice, architectural analysis, and regulatory frameworks, and is illustrated through comparative analysis and a proposed reference architecture. Organizations adopting this approach can reduce application backlogs, accelerate digital transformation, and maintain regulatory confidence, with the framework remaining extensible to other regulated manufacturing sectors.
Keywords
Low-Code/No-Code, Manufacturing Execution System, Digital Manufacturing, GxP Compliance, Pharmaceutical Manufacturing, Medical Devices
References
Alarcón, F., et al. (2025). Conceptual frameworks for industrial modernization: Toward digital technology adoption in manufacturing. [Industry 4.0 conceptual study].
Dieguez, T., & Machado, J. (2025). MES evolution and integration with Industry 4.0: A global review of trends including AI and digital twins.
Gaffley, G., & Pelser, T. G. (2025). Strategic models for digital transformation toward smart, AI-integrated manufacturing systems.
Gomes, M. M., et al. (2024). Key factors for implementing MES in Industry 4.0 contexts for small and medium-sized enterprises.
Joshi, K., Sinha, A., & Dhuri, S. (2025). Transformative trends in Pharma 4.0: Digital technologies in pharmaceutical manufacturing.
Kumar Parimi, V. (2025). Impact of low-code/no-code platforms on digital transformation, productivity, and innovation across enterprises.
Nurdiyanto, H., & Kindiasari, R. (2024). The critical role of Manufacturing Execution Systems in digital transformation and real-time decision-making.
Ozman, S. (2025). A systematic literature review of current developments in low-code/no-code (LCNC) solutions, including governance and scalability considerations.
Pokhrel, S., Sapkota, R., & Ghimire, B. (2025). The role of low-code/no-code platforms in enterprise digital transformation.
Sahay, A., et al. (2021). Low-code/no-code platforms: Concept, characteristics, and adoption implications.
Sanchis, R., et al. (2020). Low-code as an enabler of digital transformation in manufacturing contexts.
Tabim, V. M., et al. (2024). MES 4.0 implementation challenges and the role of knowledge sharing during Industry 4.0 transitions.
Tetteh, M. G., Jagtap, S., & Salonitis, K. (2023). Pharma 4.0: Revealing drivers of the digital transformation in the pharma sector. In H. Kohl, G. Seliger, & F. Dietrich (Eds.), Manufacturing Driving Circular Economy (Lecture Notes in Mechanical Engineering). Springer. https://doi.org/10.1007/978-3-031-28839-5_59
Journal of Young Pharmacists. (2025). Pharma 4.0: Enhancing process robustness in pharmaceutical manufacturing through Industry 4.0 integration. https://doi.org/10.5530/jyp.20250104
ScienceDirect / Sustainable Chemistry and Pharmacy. (2023). Impact of GAMP 5, data integrity, and QbD on quality assurance in the pharmaceutical industry: How obvious is it?
Saeedi, M. (2025). Digital twins as an advanced Industry 4.0 technology: A review relevant to manufacturing analytics.
Lamanna, J. (2025). Structured evaluation criteria for selecting low-code platforms in enterprise digital strategy. [Industry analysis].
Verified Market Reports. (2025). Market forecast analysis of low-code/no-code development platform adoption in manufacturing. [Industry/market report].
Business Research Insights. (2025). Market growth and drivers for MES adoption in the pharmaceutical sector. [Industry/market report].
Research & Markets. (2025). Low-code development platform market size and adoption trends. [Industry/market report].
ResearchGate. (2025). Case outcomes from MES deployment showing operational performance improvements. [Supplementary industry case material].
Download and View Statistics
Copyright License
Copyright (c) 2026 Dhaval Sikligar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.